Biggest loser is a terminal death for MAIS:Maistro. They have decided it's in the best interest of shareholders to de-list. In the best interest of which shareholders exactly? Not surprisingly this caused a 79% drop in share price based on their share price on the day. As they have already collapsed it was only a 13% drop on the price I paid for them, but the decline with commission is now 107% and if I sold them I would lose £8 due to the commission. This was one of my first and most foolish purchases when they were BLUR:Blur Group so I only spent £122 and regretted it ever since. I won't give them the satisfaction of selling, but my shares will be in limbo and I may never be able to get rid of them.
Next worst performer is a real mystery. TLOU:Tlou Energy dropped 10% and it seems to be linked with a newspaper announcement that their tender for a gas power station has been accepted and now negotiations will begin. It was all a bit vague as they said the same for the rival company, so until clarification is received we don't know what's happening. Best case scenario is that they have decided to go ahead with both projects, but we shall see. The drop means these are 24% down now, but still worth £2,077 and my target is only to make 20%, although if they get the tender then it may rocket.
Another 10% drop this week was VRS:Versarien which I decided not to trade despite being pretty certain it would be volatile. I'm regretting that decision now as I've lost about £250 paper profit already, but they are still up by £68.
There was more good news for TEK:Tekcapital this week, whose invested companies seem to be making good progress. This may be one of the few IP companies that actually does OK. Despite the 7% increase, my holding is still down 26% and losing £125 in the trading account.
OPTI:Optibiotix climbed by 6p which is 9% and took paper profits in the three accounts to £12,135. Normally that would result in a top-slice, but no way with this baby!
For the 2nd week in a row OPTI:Optibiotix spin-off SBTX:SkinBioTherapeutics wins Share of the Week. Last week it went up 17% and this week 10% and is now back in profit by 6% and making £115. I'm still a bit nervous about what's going to happen about the "dividend" from the sell-off, as it's not going to be in SBTX:SkinBioTherapeutics shares and I probably won't be able to afford to buy them if it's a cash payout as everyone will have the same idea. I'm worried I'll lose a big part of my original OPTI:Optibiotix holding with little reward. What's more worrying is the same might happen when the ProBiotics division is spun off.
Not quite caught up with the line, but nearly.
Back above the trend line - much celebration! Look how steep it's got though - most worrying.
Here's the ISA and Share portfolios' performance
| Weekly Change | |||
| Cash | £50.79 | +£27.57 | |
| Portfolio cost | £57,274.78 | +£0 | |
| Portfolio sell value (bid price - commission) | £55,556.51 | (-3%) | +£3,179.83 |
| Potential profits | £8,162.60 | +£3,125.11 | |
| Yr 4 Dividends | £88.07 | +£27.57 | |
| Yr 4 Profit from sales | £1,077.60 | +£0 | |
| Yr 4 Average monthly cash profit | £119.63 | (2.5%) | -£0.01 |
| Total Dividends | £1,326.40 | +£27.57 | |
| Total Profit from sales | £19,774.72 | +£0 | |
| Average monthly cash profit | £460.19 | (9.6%) | -£1.74 |
| (Sold stocks profit + Dividends - Fees / Months) |
Cash increased thanks to the £27.57 CEY:Centamin dividend. That also reduced the drop in average monthly performance but not by a whole lot as it's such a tiny amount. Paper profits soared, and the portfolio value increased by an extra £50 so a few reduced losses too.
Still a way to go before catching up with the red line. Look how flat that is - I've hardly sold anything in this account for a long time, and not added anything to my ISA.
Although still in the red, at least this is back above the trend line.
The SIPP looks like this after week 181
| Weekly Change | |||
| Cash | £127.54 | +£68.24 | |
| Portfolio cost | £40,725.38 | +£0 | |
| Portfolio sell value (bid price - commission) | £41,880.48 | (2.8%) | +£1,643.38 |
| Potential profits | £4,499.36 | +£1,626.88 | |
| Yr 4 Dividends | £68.23 | +£68.23 | |
| Yr 4 Interest | £0.07 | +£0.01 | |
| Yr 4 Profit from sales | £732.65 | +£0 | |
| Yr 4 Average monthly cash profit | £125.75 | (3.7%) | +£7.08 |
| Total Dividends | £1,410.48 | +£68.23 | |
| Total Interest | £0.10 | +£0.01 | |
| Total Profit from sales | £11,277.57 | +£0 | |
| Average monthly cash profit | £295.21 | (8.7%) | +£0 |
| (Sold stocks profit + Dividends - Fees / Months) |
A bigger £68.23 CEY:Centamin dividend in this one, and 1p interest - woohoo! Good increase in potential profits and a tiny reduction in losses by £20. The big hit was VRS:Versarien dropping 10% and chewing up some of the potential profits.
It's amazing how this portfolio just hates being in the red. After only the 4th brief dalliance in the last 12 months it's back in the black.
So although we're up above the £0 line, we're still below the trend line and the mountain from 10 months ago is looming on the trend line horizon.
Here's the trading account after week 147.
| Weekly Change | |||
| Cash | £18.80 | +£0 | |
| Portfolio cost | £2,321.29 | +£0 | |
| Portfolio sell value (bid price - commission) | £1,582.57 | (-31.8%) | +£15.04 |
| Potential profits | £0 | +£0 | |
| Year 3 Dividends | £17.33 | +£0 | |
| Year 3 Profit | £177.06 | +£0 | |
| Yr 3 Average monthly cash profit | £19.59 | (10.1%) | -£0.47 |
| Dividends | £18.48 | +£0 | |
| Profit from sales | -£64.29 | +£0 | |
| Average monthly cash profit | -£1.35 | (-0.7%) | +£0.01 |
| (Sold stocks profit + Dividends - Fees / Months) |
A solid week, climbing £15 thanks to TEK:TekCapital and despite drops in both CAML:Central Asia Metals and IQE:IQE. I'm getting increasingly concerned about LION:Lionsgold. They surely should have re-listed by now? Is the CEO about to pull off a massive heist?
Still pretty desperate
We're gradually dragging the trend line upwards, which is the only good thing you could say.
Only one certainly next week and it's the arrival of the big meaty CAML:Central Asia Metals dividend. Aside from that I can hope for positive clarification on the TLOU:Tlou Energy ITT, and hope for another big OPTI:Optibiotix deal to keep the momentum going. Still waiting for TND:Tandem Group to climb that teensy bit that will let me sell them for a profit. Current beneficiary will be CAML:Central Asia Metals as it's stupidly cheap.
No comments:
Post a Comment